Inhalable Antibodies for SARS-CoV-2
Inhalable Antibodies for SARS-CoV-2
Respiratory Disease
Breathing easier with statins?
InVixa, UC Davis team up to develop inhaled statins for the treatment of COVID-19
Agreeing on antibiotics
Hoth Therapeutics collaborates with USAMRDC to treat multi-drug resistant bacterial lung infections
Amgen licenses AMG 634 to MDGH
AMG 634, an investigational treatment for tuberculosis and leprosy, has been licensed to Medicines Development for Global Health
COVID-19 vaccine candidate COVI-VAC heads to Phase 1
COVI-VAC is a single dose, intranasal live attenuated vaccine for COVID-19
OX40L and CD30L blockade could improve asthma
Study suggests that future asthma therapies should target OX40L and CD30L
An oral option for gastrointestinal problems
Zeposia could help solve the unmet need of more oral drugs for moderate to severe CD and UC patients
Trying to take pediatric brain tumors down a peg
Ziopharm Oncology doses first DIPG patient in Phase 1/2 trial of Controlled IL-12
Looking at the frontrunners
Three compounds are in the spotlight now as new and repurposed drug options are examined for COVID-19
Anti-inflammatory TAT CARMIL1 discovery offers hope for COVID-19
Peptide combination could be effective in reducing damage caused by COVID-19 infections
Galectin Therapeutics begins enrollment in NASH-RX trial
Belapectin has shown ability to prevent the development of esophageal varices in NASH patients
